Hereditary MTC is a different clinical context than other hereditary cancer syndromes (e.g., BRCA1, BRCA2), where penetrance is significantly lower, the genetic test can yield ambiguous results, and the effectiveness and perceived benefits of "treatment" is unknown or has significant side effects. The gene discussed is BRCA2; the disease is medullary thyroid gland carcinoma.